Press releases
-
-
Internal link ProQR Announces Management Change and Key Promotions
-
Internal link ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference
-
-
Internal link ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis
-
Internal link ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology
-
-
-
Internal link ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics
-
Internal link ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
-
-
Internal link ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong
-
Internal link ProQR Announces Results for the Second Quarter of 2017
-
Internal link ProQR’s Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
-
Internal link ProQR R&D day Highlights Progress on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology
-
Internal link ProQR to Participate in a Cystic Fibrosis Panel Discussion during the JMP Securities Life Science Conference
-
-
Internal link ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10
-
Internal link ProQR Announces Results for the First Quarter of 2017
-
-
Internal link ProQR Announces R&D Day in New York on June 15
-
-
-
-
Internal link ProQR Announces Annual Meeting of Shareholders